Literature review

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue SUPPL. 1, 2005, Pages 1-7

  Hay, R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Combination therapy; Diagnosis; Epidemiology; Onychomycosis

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; POSACONAZOLE; POTASSIUM HYDROXIDE; RAVUCONAZOLE; RIBOSOME DNA; TERBINAFINE; TIOCONAZOLE; VORICONAZOLE;

ASIA; CANDIDA; CLIMATE CHANGE; CLINICAL TRIAL; DERMATOPHYTE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG POTENTIATION; EUROPE; FUNGAL EXAMINATION; FUNGAL GENETICS; FUNGAL VIRULENCE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; ONYCHOMYCOSIS; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; REINFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; ADULT; AGE DISTRIBUTION; AGED; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HOSPITALIZATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREVALENCE; PROGNOSIS; RECURRENT DISEASE; SEX RATIO; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASIA; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; PREVALENCE; PROGNOSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 28444448007     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01288.x     Document Type: Review

References (23)

1. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003; 149: 1-4.
2. Ellis DH. Diagnosis of onychomycosis made simple. J Am Acad Dermatol 1999; 40: S3-S8.
3. Hay RJ, Baran R. Deep dermatophytosis: rare infections or common, but unrecognized, complications of lymphatic spread? Curr Opin Infect Dis 2004; 17: 77-79.
4. Burzykowski T, Molenberghs G, Abeck D et al. High prevalence of foot diseases in Europe: results of the Achilles Project. Mycoses, 2003; 46: 496-505.
5. Fletcher CL, Hay RJ, Smeeton NC. Onychomycosis: the development of a clinical diagnostic aid for toenail disease. Part I. Establishing discriminating historical and clinical features. Br J Dermatol, 2004; 150: 701-705.
6. Weinberg JM, Koestenblatt EK, Tutrone WD et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 2003; 49: 193-197.
7. Rea C, Greenawald MH. What is the best method of diagnosing onychomycosis? J Fam Pract 2003; 52: 929-930.
8. Jackson CJ, Barton RC, Evans EG. Species identification and strain differentiation of dermatophyte fungi by analysis of ribosomal-DNA intergenic spacer regions. J Clin Microbiol 1999; 37: 931-936.
9. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-544.
10. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol 2004; 140: 691-695.
11. Baran R, Feuilhade M, Combernale P et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-1183.
12. Heidecker B et al. Traitement associé dans l'onychomycose avec atteinte de la matrice. Hautnah Dermatologie 2002; 4: 33-37.
13. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. Br J Dermatol 2001; 145: 21-26.
14. Rigopoulos D, Katoulis AC, Ioannides D et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 2003; 149: 151-156.
15. Harman S, Ashbee HR, Evans EG. Testing of antifungal combinations against yeasts and dermatophytes. J Dermatol Treat 2004; 15: 104-107.
16. Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004; 42: 159-163.
17. Gupta AK, Gregurek-Novak T, Konnikov N et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and review of the literature. J Cutan Med Surg 2001; 5: 206-210.
18. Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001; 145: 3-8.
19. Gupta AK, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereal 2002; 16: 579-586.
20. Soler CP, Gerome P, Leguyadec T et al. Scytalidium dimidiatum pseudodermatophyte, agent of superficial mycoses and phaehyphomycosis. Med Trop (Mars) 1999; 59: 375-377.
21. Lacroix C, Kac G, Dubertret L et al. Scytalidiosis in Paris, France. J Am Acad Dermatol 2003; 48: 852-856.
22. Morris-Jones R, Youngchim S, Hextall JM et al. Scytalidium dimidiatum causing recalcitrant subcutaneous lesions produces melanin. J Clin Microbiol 2004; 42: 3789-3794.
23. Youngchim S, Morris-Jones R, Hay RJ, Hamilton AJ. Production of melanin by Aspergillus fumigatus. J Med Microbiol 2004; 53: 175-181.